NKTR 250117 4.00P (NKTR250117P4000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

NKTR250117P4000

Watchlist

0.00
0.000.00%

15min DelayClose Jan 10 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

H.C. Wainwright Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $6.5
Moomoo News06:31 ET · Ratings
BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $4
Moomoo NewsJan 11 10:32 ET · Ratings
Buy Rating for Nektar Therapeutics: Promising Clinical Trial Strategy and Efficacy of Rezpeg
TipRanksJan 11 10:27 ET · Ratings
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $7
Moomoo NewsJan 10 07:34 ET · Ratings
Express News | Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Ad Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Moderate-to-Severe Atopic Dermatitis
ReutersJan 10 07:00 ET
Nektar Therapeutics (NKTR) Gets a Buy From Piper Sandler
TipRanksJan 10 06:46 ET · Ratings

Comments

Teddy123

Jan 10 06:20

Clinical research analysis

$Nektar Therapeutics (NKTR.US)$
The completion of target enrollment in REZOLVE-AD Phase 2b trial represents a significant milestone for Nektar's rezpegaldesleukin program. The 396-patient study achieved enrollment in just 14 months, indicating strong interest from both physicians and patients. The trial's design is particularly robust with its multi-regional approach spanning Europe (67%), US (17%), Canada (11%) and Australia (5%).
The study's focus on treatment-naïve p...

Trytosaveabit

Jan 10 06:01

Update

$Nektar Therapeutics (NKTR.US)$ Reuters· just
Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Ad Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Moderate-to-Severe Atopic Dermatitis

Teddy123

Jan 6 11:55

Recap on positive Financial analysis

$Nektar Therapeutics (NKTR.US)$
For Nektar Therapeutics, with its modest market cap of $193.7M, these results could be transformative. The CAR-T therapy market is projected to grow significantly and NKTR-255's potential to enhance existing CAR-T treatments positions it well for partnerships or licensing deals. The data showing superior complete response rates compared to historical benchmarks could translate to significant market opportunity, especially given t...

Teddy123

Dec 10, 2024 07:13

Recap: Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual AS

$Nektar Therapeutics (NKTR.US)$
08/12/2024 - 01:00
73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months
NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold...

This_Guy

Dec 8, 2024 17:28

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Positive
73% complete response rate at 6 months vs 50% for placebo
5.8-fold improvement in CD8+ CAR-T cell kinetics compared to placebo
Two patients converted from partial to complete response with NKTR-255
Results exceeded historical benchmark data of 41-44% comple...